Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.

Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Amy Guo, PhD, James D. Griffin, MD, Andrew Peng Yu, PhD, Eric Qiong Wu, PhD

Blood (2010) 116 (21): 3437.

https://doi.org/10.1182/blood.V116.21.3437.3437

Published: 2010

Journal Articles

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Eric Qiong Wu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Denise Williams, MD, Amy Guo, PhD, Diego Ponce de Leon Barido, BA, BS, Andrew Peng Yu, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3841.

https://doi.org/10.1182/blood.V116.21.3841.3841

Published: 2010

Journal Articles

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Andrew Peng Yu, PhD, Arielle G Bensimon, BA, Maryna Marynchenko, MBA, Eric Qiong Wu, PhD, Madhav Namjoshi, PhD, Amy Guo, PhD, Solveig G Ericson, MD, PhD, Noopur Raje, MD

Blood (2010) 116 (21): 1956.

https://doi.org/10.1182/blood.V116.21.1956.1956

Published: 2010

Journal Articles

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Andrew Peng Yu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Martin Cloutier, Bsc, Denise Williams, MD

Blood (2010) 116 (21): 4758.

https://doi.org/10.1182/blood.V116.21.4758.4758

Published: 2010

Journal Articles

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Andrew Peng Yu, PhD, Andres Sirulnik, MD, PhD, James D Griffin, MD

Blood (2009) 114 (22): 4270.

https://doi.org/10.1182/blood.V114.22.4270.4270

Published: 2009

NARROW

Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Email alerts

ASH Publications

American Society of Hematology

Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only